An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

A Phase I Study of BMS-986299 as Monotherapy and in Combination With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers

The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors. In addition, the ability of study drugs to stimulate an immune response against cancer will be investigated.

Inclusion Criteria:

• Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant
• IO therapy resistant or insensitive tumors
• Have at least 2 tumor lesions accessible for biopsy
• Eastern Cooperative Oncology Group Performance Status of 0 or 1

Exclusion Criteria:

• Primary CNS malignancy
• Participants with other active malignancy requiring concurrent intervention
• Uncontrolled or significant cardiovascular disease

Other protocol-defined inclusion/exclusion criteria apply